Prior evidence that VEGF-B protects against Dox-induced cardiotoxicity in mice (13), together with results from GSEA analysis and reduced VEGF-B expression in patients with BC after CTx (Figure 6A), led us to explore the utility of VEGF-B before treatment to prevent the detrimental effects of Dox or TZM exposure on human microvascular function ex vivo. This evidence concerns the gene VEGFB and breast cancer.